GlassScriptPhysician profile
Maan Younes
NPI 1245232479
$5,010.42
in general payments reported to CMS, 2019-2025
27 companies · $793 in 2025
The $793 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,345 · 2020: $465 · 2021: $637 · 2022: $860 · 2023: $295 · 2024: $617 · 2025: $793.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,648 · Education: $56.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,647.72 |
| Education | $56.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,811.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,082.61 | 2019-2025 | Breztri, Lynparza |
| Sunovion Pharmaceuticals INC. | $482.68 | 2019-2021 | |
| Insmed, INC. | $291.64 | 2019-2025 | Brinsupri, Arikayce |
| United Therapeutics Corporation | $260.77 | 2019-2025 | Tyvaso, Tyvaso |
| Medtronic Vascular, INC. | $190.60 | 2019 | |
| Mylan Specialty L.P. | $176.69 | 2019-2024 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.28 | 2019-2025 | Jascayd, Ofev |
| Regeneron Healthcare Solutions, INC. | $92.89 | 2022-2025 | Dupixent |
| Bayer Healthcare Pharmaceuticals INC. | $80.52 | 2019-2025 | |
| Genentech USA, INC. | $39.42 | 2024-2025 | Polivy, Tecentriq, Phesgo |
| Merck Sharp & Dohme LLC | $36.64 | 2024 | Keytruda, Winrevair |
| Inari Medical, INC. | $29.96 | 2020 | |
| Pharmaessentia USA Corporation | $27.75 | 2024 | Besremi |
| Geron Corporation | $27.51 | 2024 | Rytelo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $22.02 | 2024 | Enhertu |
| Baxter Healthcare | $21.92 | 2022 | |
| Tactile Systems Technology INC | $21.15 | 2023 | Flexitouch Plus, Entre Plus |
| Actelion Pharmaceuticals US, INC. | $18.98 | 2020 | |
| Verona Pharma, INC. | $17.28 | 2025 | Ohtuvayre |
| Ipsen Biopharmaceuticals, INC | $16.75 | 2020 | |
| Viatris Specialty LLC | $16.64 | 2025 | Yupelri |
| Eusa Pharma (US) LLC | $16.29 | 2019 | |
| Celgene Corporation | $16.03 | 2019 | |
| Philips North America LLC | $15.78 | 2025 | Vest Therapy Und |
| Grifols USA, LLC | $12.84 | 2019 | |
| Inogen, INC. | $7.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maan Younes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.